Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $305.100 million which missed the analyst consensus estimate of $307.035 million by 0.63 percent. This is a 56.42 percent increase over sales of $195.053 million the same period last year.